These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35865473)
1. Patient-Specific Assays Based on Whole-Genome Sequencing Data to Measure Residual Disease in Children With Acute Lymphoblastic Leukemia: A Proof of Concept Study. Arthur C; Rezayee F; Mogensen N; Saft L; Rosenquist R; Nordenskjöld M; Harila-Saari A; Tham E; Barbany G Front Oncol; 2022; 12():899325. PubMed ID: 35865473 [TBL] [Abstract][Full Text] [Related]
2. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study. Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE Front Oncol; 2023; 13():1176698. PubMed ID: 37333831 [TBL] [Abstract][Full Text] [Related]
3. Simultaneous Ultra-Sensitive Detection of Structural and Single Nucleotide Variants Using Multiplex Droplet Digital PCR in Liquid Biopsies from Children with Medulloblastoma. Arthur C; Jylhä C; de Ståhl TD; Shamikh A; Sandgren J; Rosenquist R; Nordenskjöld M; Harila A; Barbany G; Sandvik U; Tham E Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046633 [TBL] [Abstract][Full Text] [Related]
4. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647 [TBL] [Abstract][Full Text] [Related]
5. Transferring measurable residual disease measurement in pediatric acute lymphoblastic leukemia from quantitative real-time PCR to digital droplet PCR. Luib L; Kreyenberg H; Michaelis S; Handgretinger R; Mezger M Pediatr Transplant; 2023 Jun; 27(4):e14483. PubMed ID: 36750990 [TBL] [Abstract][Full Text] [Related]
7. Nanopore sequencing of clonal IGH rearrangements in cell-free DNA as a biomarker for acute lymphoblastic leukemia. Sampathi S; Chernyavskaya Y; Haney MG; Moore LH; Snyder IA; Cox AH; Fuller BL; Taylor TJ; Yan D; Badgett TC; Blackburn JS Front Oncol; 2022; 12():958673. PubMed ID: 36591474 [TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681 [TBL] [Abstract][Full Text] [Related]
9. Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia. Della Starza I; De Novi LA; Elia L; Bellomarino V; Beldinanzi M; Soscia R; Cardinali D; Chiaretti S; Guarini A; Foà R Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672325 [TBL] [Abstract][Full Text] [Related]
10. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies? Assanto GM; Del Giudice I; Della Starza I; Soscia R; Cavalli M; Cola M; Bellomarino V; Di Trani M; Guarini A; Foà R Front Oncol; 2023; 13():1152467. PubMed ID: 36998457 [TBL] [Abstract][Full Text] [Related]
11. High-throughput sequencing of peripheral blood for minimal residual disease monitoring in childhood precursor B-cell acute lymphoblastic leukemia: A prospective feasibility study. Bartram J; Wright G; Adams S; Archer P; Brooks T; Edwards D; Hancock J; Knecht H; Inglott S; Mountjoy E; Roynane M; Wakeman S; Moppett J; Hubank M; Goulden N Pediatr Blood Cancer; 2022 Mar; 69(3):e29513. PubMed ID: 34971078 [TBL] [Abstract][Full Text] [Related]
12. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia. Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572 [TBL] [Abstract][Full Text] [Related]
13. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394 [TBL] [Abstract][Full Text] [Related]
14. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia. Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184 [TBL] [Abstract][Full Text] [Related]
15. A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCR. Schwinghammer C; Koopmann J; Chitadze G; Karawajew L; Brüggemann M; Eckert C J Mol Diagn; 2022 Aug; 24(8):856-866. PubMed ID: 35691569 [TBL] [Abstract][Full Text] [Related]
16. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]. zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545 [TBL] [Abstract][Full Text] [Related]
17. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia]. Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363 [TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances. Della Starza I; Chiaretti S; De Propris MS; Elia L; Cavalli M; De Novi LA; Soscia R; Messina M; Vitale A; Guarini A; Foà R Front Oncol; 2019; 9():726. PubMed ID: 31448230 [No Abstract] [Full Text] [Related]
19. Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia. Della Starza I; Nunes V; Lovisa F; Silvestri D; Cavalli M; Garofalo A; Campeggio M; De Novi LA; Soscia R; Oggioni C; Mussolin L; Biondi A; Guarini A; Valsecchi MG; Conter V; Biffi A; Basso G; Foà R; Cazzaniga G Hemasphere; 2021 Mar; 5(3):e543. PubMed ID: 33655199 [TBL] [Abstract][Full Text] [Related]
20. [A tal-1 deletion as real-time quantitative polymerase chain reaction target for detection of minimal residual disease in T-lineage acute lymphoblastic leukemia]. Wang L; Zhang LP; Li ZG; Cheng YF; Tian KG; Lu AD Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):170-3. PubMed ID: 15833185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]